Infection with a high-risk human papillomavirus strain has been proved as a crucial element causing cervical cancer, which making the inclusion of hrHPV test in cervical screening programs. The HPV test will indicate a woman’s risk of developing cervical cancer by detecting the presence of oncogenic hrHPV in the cells of the cervix. If the oncogenic hrHPV is not detected, the woman is at low risk of developing significant cervical cancer precursors within the next five years.
　　The increasing use of hrHPV test makes challenges to the anatomic pathological laboratory services, such as different thoughts of quality management for this molecular test. As articulated in the European guidelines for quality assurance in cervical cancer screening: optimal screening performance is achieved through a national approach, implicit in which are guidelines for training, re-call and management, key performance indicators, and external and internal quality assessment. We will discuss some of the quality considerations and challenges with much emphasis on the laboratory management such as performance characters of assay and platform, and issues of quality assurance.